New drug for prostate cancer after lutetium treatment
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new drug called xaluritamig for men with advanced prostate cancer that has not responded well to a standard treatment called lutetium-177. The goal is to see if this drug can help control the cancer when other treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with prostate cancer that has spread (metastatic).
- You have had surgery to remove the testicles or are on hormone therapy to keep testosterone levels low.
- You have already been treated with at least one newer hormone therapy like enzalutamide or abiraterone.
- You have completed 2 cycles of lutetium-177 treatment, with your last dose between 6 and 16 weeks before starting this study, and your PSA levels dropped some but not completely.
- You are willing to use birth control if you have a partner who could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called xaluritamig given before surgery for men with localized prostate cancer that is intermediate or high risk. The goal is to see if it can help shrink the cancer before the prostate is removed.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This trial tests a new radioactive treatment, called 177Lu-NYM032, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It aims to see if this treatment can slow the cancer's growth and improve outcomes.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
This trial tests a radioactive drug (lutetium) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if it can shrink the tumor and improve outcomes.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.